Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma

Published:2019-04-03 Issue:10 Volume:60 Page:2516-2523
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Biccler Jorne L.¹²,Savage Kerry J.³,Brown Peter D.N.⁴,Jørgensen Judit⁵,Larsen Thomas S.⁶,Poulsen Christian B.⁷,Stoltenberg Danny⁸,Sehn Laurie H.³,Scott David W.³,Gerrie Alina S.³,Jakobsen Lasse H.¹²,Bøgsted Martin¹²,El-Galaly Tarec C.¹²,Villa Diego³^ORCID

Affiliation:

1. Department of Haematology, Aalborg University Hospital, Aalborg, Denmark;

2. Department of Clinical Medicine, Aalborg University, Aalborg, Denmark;

3. BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada;

4. Department of Haematology, Copenhagen University Hospital, Copenhagen, Denmark;

5. Department of Haematology, Aarhus University Hospital, Aarhus, Denmark;

6. Department of Haematology, Odense University Hospital, Odense, Denmark;

7. Department of Haematology, Roskilde Sygehus, Roskilde, Denmark;

8. Department of Haematology, Herlev and Gentofte Hospital, Copenhagen, Denmark

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2019.1594219

Reference29 articles.

1. Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment

2. Trends in primary central nervous system lymphoma incidence and survival in the U.S.

3. Pathology and Genetics of Primary Central Nervous System and Intraocular Lymphoma

4. Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study

5. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy;Haematologica;2023-09-14

2. Specific KIR-HLA genotypes predict outcomes in refractory or relapsed primary central nervous system lymphoma;Hematology;2023-08-07

3. A Systematic Review of Cognitive Function, Anxiety, and Depression in Patients With Newly Diagnosed Primary Central Nervous System Lymphoma;Biological Research For Nursing;2023-08-04

4. A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis;Frontiers in Oncology;2023-03-28

5. Cerebrospinal fluid metabolic markers predict prognosis behavior of primary central nervous system lymphoma with high-dose methotrexate-based chemotherapeutic treatment;Neuro-Oncology Advances;2022-12-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3